<DOC>
	<DOCNO>NCT02312089</DOCNO>
	<brief_summary>Evaluation effect add single dose gonadotropin release hormone agonist ( GnRHa ) luteal phase support outcome intracytoplasmic sperm injection ( ICSI ) follow GnRH antagonist protocol</brief_summary>
	<brief_title>GnRHa Luteal Phase Support GnRH Antagonist Protocol Cycles</brief_title>
	<detailed_description>Endometrial preparation embryo transfer ( ET ) start oocyte retrieval give 800 mg/day natural progesterone vaginal supplement + 4 mg/day estradiol oral supplement . The patient randomly divide 2 group luteal phase support : ( ) Group A ( GnRHa group ) luteal phase support continue regimen start day oocyte retrieval 2 week embryo transfer ( ET ) subcutaneous administration single dose ( 0.2 mg ) GnRHa ( Triptorelin ) 6 day oocyte retrieval , ( ii ) Group B ( control group ) luteal phase support continue regimen start day oocyte retrieval 2 week ET</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Women subject ICSI control ovarian hyperstimulation ( COH ) pituitary downregulation GnRH antagonist . Moderate severe endometriosis . Hydrosalpinx . Uterine abnormality . Myoma . Previous uterine surgery .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Luteal phase support , ICSI , GnRHa</keyword>
</DOC>